Artemis Therapeutics Inc. (OTCMKTS:ATMS – Get Rating) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 900 shares, a decline of 18.2% from the August 31st total of 1,100 shares. Based on an average daily trading volume, of 1,200 shares, the short-interest ratio is presently 0.8 days.
Artemis Therapeutics Stock Performance
Shares of Artemis Therapeutics stock traded up $0.30 on Friday, hitting $3.00. 5,022 shares of the company's stock traded hands, compared to its average volume of 1,159. The firm's 50-day moving average price is $1.81 and its two-hundred day moving average price is $2.26. Artemis Therapeutics has a one year low of $0.55 and a one year high of $5.00.
Get Artemis Therapeutics alerts:About Artemis Therapeutics
(Get Rating)
Artemis Therapeutics Inc does not have significant operations. Previously, it was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company is based in New York, New York. Artemis Therapeutics Inc is a subsidiary of Tonak Ltd.Read More
- Get a free copy of the StockNews.com research report on Artemis Therapeutics (ATMS)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Thor Industries Hammers Out A Bottom
Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.